TY - JOUR
T1 - COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes
T2 - a multicenter case–control study
AU - Hong, Simon J.
AU - Bhattacharya, Sumona
AU - Aboubakr, Aiya
AU - Nadkarni, Devika
AU - Lech, Diana
AU - Ungaro, Ryan C.
AU - Agrawal, Manasi
AU - Hirten, Robert P.
AU - Greywoode, Ruby
AU - Mone, Anjali
AU - Chang, Shannon
AU - Hudesman, David P.
AU - Ullman, Thomas
AU - Sultan, Keith
AU - Lukin, Dana J.
AU - Colombel, Jean Frederic
AU - Axelrad, Jordan E.
N1 - Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Ryan C. Ungaro receives research support from the NIH NIDDK K23KD111995-01A1. Manasi Agrawal receives research support from the NIH NIDDK K23DK129762-01. Robert Hirten receives research support from the NIH NIDDK K23DK129835. Jordan Axelrad receives research support from the Crohn’s and Colitis Foundation, the Judith & Stewart Colton Center for Autoimmunity, Lyanne and Michael Saperstein, and the NIH NIDDK Diseases K23DK124570.
Funding Information:
Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals, and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Ferring Pharmaceuticals, Galmed Research, Glaxo Smith Kline, Geneva, Iterative Scopes, Janssen Pharmaceuticals, Kaleido Biosciences, Landos, Otsuka, Pfizer, Prometheus, Sanofi, Takeda, TiGenix; and hold stock options in Intestinal Biotech Development.
Funding Information:
David P. Hudesman has received research grants from Pfizer; served as a consultant for Abbvie, BMS, Janssen, Takeda, Pfizer, and Samsung.
Funding Information:
Keith Sultan has received research funding from Abbvie, BMS, and Takeda.
Publisher Copyright:
© The Author(s), 2022.
PY - 2022
Y1 - 2022
N2 - Background: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disease course of IBD. Objectives: We aimed to investigate the effect of COVID-19 on long-term outcomes of IBD. Design: We performed a multicenter case–control study of patients with IBD and COVID-19 between February 2020 and December 2020. Methods: Cases and controls were individuals with IBD with presence or absence, respectively, of COVID-19-related symptoms and confirmatory testing. The primary composite outcome was IBD-related hospitalization or surgery. Results: We identified 251 cases [ulcerative colitis (n = 111, 45%), Crohn’s disease (n = 139, 55%)] and 251 controls, with a median follow-up of 394 days. The primary composite outcome of IBD-related hospitalization or surgery occurred in 29 (12%) cases versus 38 (15%) controls (p = 0.24) and on multivariate Cox regression, COVID-19 was not associated with increased risk of adverse IBD outcomes [adjusted hazard ratio (aHR): 0.84, 95% confidence interval [CI]: 0.44–1.42]. When stratified by infection severity, severe COVID-19 was associated with a numerically increased risk of adverse IBD outcomes (aHR: 2.43, 95% CI: 1.00–5.86), whereas mild-to-moderate COVID-19 was not (aHR: 0.68, 95% CI: 0.38–1.23). Conclusion: In this case–control study, COVID-19 did not have a long-term impact on the disease course of IBD. However, severe COVID-19 was numerically associated with worse IBD outcomes, underscoring the continued importance of risk mitigation and prevention strategies for patients with IBD during the ongoing COVID-19 pandemic.
AB - Background: Inflammatory bowel disease (IBD) is not associated with worse coronavirus disease 2019 (COVID-19) outcomes. However, data are lacking regarding the long-term impact of severe acute respiratory syndrome coronavirus 2 infection on the disease course of IBD. Objectives: We aimed to investigate the effect of COVID-19 on long-term outcomes of IBD. Design: We performed a multicenter case–control study of patients with IBD and COVID-19 between February 2020 and December 2020. Methods: Cases and controls were individuals with IBD with presence or absence, respectively, of COVID-19-related symptoms and confirmatory testing. The primary composite outcome was IBD-related hospitalization or surgery. Results: We identified 251 cases [ulcerative colitis (n = 111, 45%), Crohn’s disease (n = 139, 55%)] and 251 controls, with a median follow-up of 394 days. The primary composite outcome of IBD-related hospitalization or surgery occurred in 29 (12%) cases versus 38 (15%) controls (p = 0.24) and on multivariate Cox regression, COVID-19 was not associated with increased risk of adverse IBD outcomes [adjusted hazard ratio (aHR): 0.84, 95% confidence interval [CI]: 0.44–1.42]. When stratified by infection severity, severe COVID-19 was associated with a numerically increased risk of adverse IBD outcomes (aHR: 2.43, 95% CI: 1.00–5.86), whereas mild-to-moderate COVID-19 was not (aHR: 0.68, 95% CI: 0.38–1.23). Conclusion: In this case–control study, COVID-19 did not have a long-term impact on the disease course of IBD. However, severe COVID-19 was numerically associated with worse IBD outcomes, underscoring the continued importance of risk mitigation and prevention strategies for patients with IBD during the ongoing COVID-19 pandemic.
KW - COVID-19
KW - inflammatory bowel disease
KW - long term
KW - outcomes
UR - http://www.scopus.com/inward/record.url?scp=85141781640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141781640&partnerID=8YFLogxK
U2 - 10.1177/17562848221132363
DO - 10.1177/17562848221132363
M3 - Article
AN - SCOPUS:85141781640
VL - 15
JO - Therapeutic Advances in Gastroenterology
JF - Therapeutic Advances in Gastroenterology
SN - 1756-283X
ER -